---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023779"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:10:18.331996+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# INVO Fertility Q3 revenue up 23% to $1.76M; net loss widens to $2.6M

## Summary
- Revenue $1,757,094 (+23% YoY); clinic revenue $1,722,223 (+21% YoY).
- Net loss $(2.6)M vs $(1.6)M; Adjusted EBITDA $(947,568) vs $(945,949).
- INVOcell device revenue grew 130% YoY on training support and pricing.
- Company expects to complete at least one acquisition in coming months.
- Federal policy change in Oct 2025 allows standalone infertility benefits.

## SEC filing metadata
- accession: 0001493152-25-023779
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315225023779/0001493152-25-023779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315225023779/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023779
- JSON: https://secwatch.observer/filing/0001493152-25-023779.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.